乳腺癌^99mTc—MIBI显像与多药耐药类蛋白关系

The relationship between ^99mTc - MIBI scintimammography of breast cancer and multidrug - resistant proteins

目的研究甲氧基异丁基异腈（^99mTc—MIBI）亲肿瘤显像与乳腺癌多药耐药类蛋白P-糖蛋白（P—gp）、谷胱甘肽-S-转移酶-π（GST-π）和拓扑异构酶Ⅱ（TopoⅡ）的关系。方法对76例未行治疗的乳腺癌患者进行^99mTc—MIBI显像，采集10min及180min两时相的平面像，计算放射性清除率；采用免疫组化方法，对术后病理组织进行多药耐药类蛋白检测。结果P—gp阳性组清除率明显高于阴性组，差异有统计学意义；GST-π和TopoⅡ表达率与清除率无明显关系。结论^99mTcTc—MIBI亲肿瘤显像可作为乳腺癌P—gp非组织学测定方法，预测化疗耐药性。

Objective To evaluate the relationship between the clearance rate of technetium ^99mTc- thoxyisobutylisonitrile （^99mTc -MIBI） in scintimammography and multidrug- resistant proteins expression in breast cancer tissues. Methods Seventy - six patients with breast cancer underwent ^99mTc - MIBI scintimammography before treatment, and static planar images were taken at 10 min and 180 min after scintimammography. The clearance rate of ^99m Tc - MIBI was calculated in each patient. Immunohistochemical analysis was perfomed on pathological specimens of the 76 breast tumors to detemine the expression of P - glycoprotein（ P - gp）, glutathione S - transferase Pi （ GST -π） and topoisomeraseⅡ （ Topo Ⅱ）. Results The clearance rate was significantly higher in 36 patients with positive P - gp expression when compared with that in 40 patients with negative P-gp expression. There was no significant relationship between GST-π, Topo II and the clearance rate of ^99mTc - MIBI. Conclusion The clearance rate of ^99mTc - MIBI in breast imaging maybe used to evaluate the P-gp level in breast cancers.